Teva Stock Buy Or Sell Direct

Most major brokerages have raised their expectations for TEVA in 2026, citing a strong research and development (R&D) pipeline and cost-cutting measures.

Teva Pharmaceutical Industries (TEVA) currently holds a consensus rating from Wall Street analysts as of April 2026 . While the company faces near-term revenue headwinds, its "Pivot to Growth" strategy—shifting focus from generics to high-margin branded therapies—has led to significant price target upgrades from major financial institutions. Analyst Consensus & Price Targets teva stock buy or sell

: $38.78 (approximately 26% upside from recent trading prices). High Estimate : $45.00 (The Goldman Sachs Group). Low Estimate : $26.00. Most major brokerages have raised their expectations for

: 10 Buy/Strong Buy ratings, 0 Hold, and 1 Sell recommendation. Key Investment Highlights Teva Pharmaceutical Industries Ltd. - News - Press Releases teva stock buy or sell